Recent experimental evidence has suggested that inhibition of GSK-3β abrogates NF-κB binding to its target gene promoters through an epigenetic mechanism and enhances apoptosis in chronic lymphocytic leukemia (CLL) B cells ex vivo [9]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.